Last reviewed · How we verify
13C-uracil
13C-uracil is a radiolabeled analog of the pyrimidine nucleoside uracil, used for PET imaging of pyrimidine metabolism.
13C-uracil is a radiolabeled analog of the pyrimidine nucleoside uracil, used for PET imaging of pyrimidine metabolism. Used for Assessment of pyrimidine metabolism in cancer.
At a glance
| Generic name | 13C-uracil |
|---|---|
| Also known as | C13-URA |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | Nucleoside |
| Target | Pyrimidine metabolism |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
13C-uracil is taken up by cells and metabolized into its nucleotide form, which is then incorporated into RNA. This process allows for the visualization of pyrimidine metabolism in the body through PET imaging.
Approved indications
- Assessment of pyrimidine metabolism in cancer
Common side effects
- Unknown
Key clinical trials
- Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects (PHASE2)
- Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |